Answers are grounded in this paper and cite their sources.
Background: JAK2V617F mutation is recurrent in MPN and reported as a marker for occult MPN in patients with splanchnic vein thrombosis. Objective: To better estimate the pattern of arterial and venous thrombosis in a Lebanese series in order to define the potential risk and to evaluate the current treatment. Methods: Ninety-five consecutive patients were included and all arterial and venous thrombotic events were documented, altogether with the clinical and demographic data. Results: Twenty-eight % of patients developed arterial thrombosis and 29% venous thrombosis with PV predilection for DVT and BCS. 27% and 5% of patients had thrombosis at presentation or history of thrombosis. However; subsequent thrombosis may develop in 20% of cases and may be the cause of death in 12.6%. Two cases with family aggregation were observed. Conclusion: Close surveillance should be carried out in JAK2V617F-mutated patients with special attention to subsequent thrombosis development. Familial clustering should be looked for.
No takes yet. Share an insight, caveat, or question.
Riad Akoum (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: